Pixium Vision announces participation in upcoming investor conferences in September 2022Antoine Balavoine2022-09-07T13:20:38+02:00September 6th, 2022|
Pixium Vision announces participation in upcoming scientific conferences in September 2022Antoine Balavoine2022-08-29T10:55:22+02:00August 29th, 2022|
Pixium Vision to attend H.C. Wainwright 2nd Annual Ophthalmology Virtual Conference on August 17, 2022Antoine Balavoine2022-08-11T11:42:46+02:00August 11th, 2022|
Pixium Vision announces regulatory approval of remote rehabilitation system for patients in clinical trialsAntoine Balavoine2022-08-03T12:13:12+02:00August 3rd, 2022|
Successful implantation of first patient in the NetherlandsAntoine Balavoine2022-07-26T09:00:44+02:00July 26th, 2022|
Pixium Vision announces its financial results for H1 2022 and provides a business updateAntoine Balavoine2022-07-25T12:08:18+02:00July 22nd, 2022|
Pixium Vision announces the implementation of a financing of a maximum nominal amount of €30 million, and the drawdown of a first tranche of €5.5 millionAntoine Balavoine2022-07-14T19:40:30+02:00July 14th, 2022|
Pixium Vision expands its Board of Directors with the appointment of Anja Krammer and August MorettiAntoine Balavoine2022-06-24T11:14:22+02:00June 24th, 2022|
Availability of audited financial statements for the financial year 2021Antoine Balavoine2022-04-29T20:03:06+02:00April 29th, 2022|
FDA approval of clinical trial expansion of Prima System US feasibility study to Stanford MedicineAntoine Balavoine2022-03-29T18:17:30+02:00March 29th, 2022|
Pixium Vision to participate in the 2022 Virtual Growth ConferenceAntoine Balavoine2022-03-24T17:38:29+01:00March 24th, 2022|
Pixium Vision announces its unaudited financial results for 2021 and provides a business updateAntoine Balavoine2022-02-22T11:34:55+01:00February 22nd, 2022|
Publication in Nature Communications of peer-reviewed clinical data demonstrating the clinical benefit of the Prima System in Dry AMD patientsAntoine Balavoine2022-01-27T18:00:14+01:00January 27th, 2022|
